SYC has mentioned a couple of times that he is aiming for PTX-100 to be modelled on Loxo. So effectively a phase 1b trial which is underway and then a confirmatory trial (equivalent to a phase three or even phase four).
[paywalled] While both PTX 100 and 200 are still early in their development, Mr Yatomi-Clarke said thanks to clever study designs (and the fact that these treatments are for patients who are dying) it would be possible to bring products to market in a relatively short amount of time, potentially after completing phase two trials. ..With refractory patients you can get to market with comparatively much smaller, much shorter development timelines, he said.
Loxo Oncology pioneered this one trial to launch... and a few guys involved in the development of their drug now work for us. It is the equivalent of doing a phase three because you're smarter with patient recruitment, he said.
PTX Price at posting:
9.5¢ Sentiment: Hold Disclosure: Held
